Kazia Therapeutics Ltd ADR KZIA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards
Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
Trading Information
- Previous Close Price
- $7.41
- Day Range
- $7.32–7.81
- 52-Week Range
- $4.86–17.40
- Bid/Ask
- $7.39 / $9.22
- Shares Outstanding
- 15.55M
- Market Cap
- $115.06M
- Volume/Avg
- 130,854 / 264,633
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 613.73
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
Valuation
Metric | KZIA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.71 |
Price/Sales | 613.73 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | KZIA |
|---|---|
Quick Ratio | 2.86 |
Current Ratio | 2.87 |
Interest Coverage | — |
Quick Ratio
KZIA
Profitability
Metric | KZIA |
|---|---|
Return on Assets (Normalized) | −38.68% |
Return on Equity (Normalized) | −107.05% |
Return on Invested Capital (Normalized) | −106.74% |
Return on Assets
KZIA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|H$$!sF | LOCK|HkG!# | $139B | |||
| Moderna Inc MRNA | LOCK|tW$!!& | LOCK|&B | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|V%qqv@n | LOCK|HQB> | $95B | |||
| argenx SE ADR ARGX | LOCK|<ZM^B@t | LOCK|$f | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|$dg!bG | LOCK|t<d | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|&nK#s&r> | LOCK|%d<xj | $31B | |||
| Incyte Corp INCY | LOCK|Wc#$>z | LOCK|?$ | $25B | |||
| BioNTech SE ADR BNTX | LOCK|T?BQ&%m | LOCK|Q% | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|tdt!Th! | LOCK|Dp^& | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|G^hK#r | LOCK|D>Y | $16B |
United States